Drugs / CL-NK-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06816823 | Apr → Sep 2025 overdue | malignant pancreatic neoplasm | Changhai Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL-NK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06816823 ↗ |
| Modality | Cell therapy | “CAR-NK cells” NCT06816823 ↗ |